Novo Nordisk began construction of a new $2 billion production facility in Clayton, NC that will produce active pharmaceutical ingredients (API) for a range of the company’s current and future GLP-1 and insulin products. When fully operational in 2020, the site will take on production capacity for diabetes care products in the U.S.   The new site is adjacent to Novo Nordisk’s existing 42,000 m2 facility, which assembles and packages FlexPen and FlexTouch prefilled insulin devices f...